Cellosaurus logo
expasy logo

Cellosaurus MDA-MB-231 (CVCL_0062)

[Text version]
Cell line name MDA-MB-231
Synonyms MDA_MB_231; MDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231; MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA-231P; MDA231; MDA231-BRE; MB231; MD Anderson-Metastatic Breast-231
Accession CVCL_0062
Resource Identification Initiative To cite this cell line use: MDA-MB-231 (RRID:CVCL_0062)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 3.
Part of: JWGray breast cancer cell line panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12532.
Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583).
Population: Caucasian.
Doubling time: 1.3 days (PubMed=9671407); 26.7 hours (PubMed=9815641); 24.7 hours (PubMed=24389870); 36.2 hours (PubMed=34238275); 38 hours (ATCC=HTB-26); ~25-30 hours (DSMZ=ACC-732); 41.9 hours (NCI-DTP=MDA-MB-231); ~38 hours (PBCF); 31.43 hours (JWGray panel).
Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
Omics: Array-based CGH.
Omics: Chromatin accessibility by ATAC-seq.
Omics: Cell surface proteome.
Omics: CNV analysis.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Exosome proteome analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: H2BK120ub ChIP-seq epigenome analysis.
Omics: H3K23ac ChIP-seq epigenome analysis.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K27me3 ChIP-seq epigenome analysis.
Omics: H3K36me3 ChIP-seq epigenome analysis.
Omics: H3K4me1 ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: H3K79me2 ChIP-seq epigenome analysis.
Omics: H3K9ac ChIP-seq epigenome analysis.
Omics: H3K9me3 ChIP-seq epigenome analysis.
Omics: H4K8ac ChIP-seq epigenome analysis.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870).
Misspelling: MDA-MB-321; Note=Occasionally.
Misspelling: MDA-MD-231; Cosmic=1071900; Cosmic=1176602.
Misspelling: MDA-321; GEO=GSM459713.
Misspelling: MDA-MG-231; PubMed=6582512.
Misspelling: MD-MB-231; PRIDE=PXD010634.
Misspelling: MD-MBA-231; Note=Occasionally.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
HLA typing Source: PubMed=77569
Class I
HLA-AA*02/28
HLA-BB*07,08
HLA-CC*w02,w06

Source: PubMed=15748285
Class I
HLA-AA*02:01,02:17
HLA-BB*40:02,41:01
HLA-CC*02:02:02,17
Class II
HLA-DPDPB1*02:01:02,17:01
HLA-DQDQB1*02:02,03:01:01
HLA-DRDRB1*07:01,13:05

Source: PubMed=25960936
Class I
HLA-AA*02:17,02:01
HLA-BB*40:02,41:01
HLA-CC*02:02,17:01
Class II
HLA-DQDQA1*02:01,02:01
DQB1*03:04,03:04
HLA-DRDRB1*07:01,13:05

Source: PubMed=26589293
Class I
HLA-AA*02:17,02:17
HLA-BB*40:02,41:01
HLA-CC*02:02,17:01
Class II
HLA-DQDQA1*01:02,01:02
DQB1*02:02,03:04
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.95
Native American0
East Asian, North2.44
East Asian, South0
South Asian7.42
European, North28.16
European, South60.03
Disease Breast adenocarcinoma (NCIt: C5214)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_EQ20 (2LMP)CVCL_A9BP (Ecad-231-7)CVCL_A9BQ (Ecad-231-9)
CVCL_E1M3 (HyCyte MDA-MB-231 KO-hCT83)CVCL_D6C5 (HyCyte MDA-MB-231 KO-hHACD2)CVCL_D6C6 (HyCyte MDA-MB-231 KO-hHNRNPA2B1)
CVCL_E1M4 (HyCyte MDA-MB-231 KO-hMUC1)CVCL_E1M5 (HyCyte MDA-MB-231 KO-hRASAL2)CVCL_D6C7 (HyCyte MDA-MB-231 KO-hSTK39)
CVCL_E1M6 (HyCyte MDA-MB-231 KO-hUSP22)CVCL_YJ86 (LINTERNA MDA-MB-231)CVCL_E1F3 (MDA-231#15 rho-0)
CVCL_DP48 (MDA-BoM-1833)CVCL_4Y38 (MDA-MB-231 25PACR)CVCL_4Y39 (MDA-MB-231 50PACR)
CVCL_A9AZ (MDA-MB-231 CAPN2 KO)CVCL_DX79 (MDA-MB-231 Cas9)CVCL_IN16 (MDA-MB-231 CMV)
CVCL_DX80 (MDA-MB-231 dCas9-VPR)CVCL_IN17 (MDA-MB-231 ERalpha)CVCL_IN15 (MDA-MB-231 ERalpha203/4/11)
CVCL_IN18 (MDA-MB-231 ERbeta)CVCL_IN19 (MDA-MB-231 ERbetaDBD)CVCL_A5ER (MDA-MB-231 met2)
CVCL_A9BB (MDA-MB-231 NAT1 down)CVCL_A9BA (MDA-MB-231 NAT1 scrambled)CVCL_A9BC (MDA-MB-231 NAT1 up)
CVCL_DF47 (MDA-MB-231 NucLight Green)CVCL_DF48 (MDA-MB-231 NucLight Red)CVCL_RA90 (MDA-MB-231 shPARG)
CVCL_YJ26 (MDA-MB-231 shWDR12-4)CVCL_S031 (MDA-MB-231 SimpleCell O-GalNAc)CVCL_VR67 (MDA-MB-231 VIM RFP)
CVCL_ZZ22 (MDA-MB-231 Vb100)CVCL_9U30 (MDA-MB-231-5a)CVCL_R956 (MDA-MB-231-BAG)
CVCL_UJ21 (MDA-MB-231-Dox)CVCL_C8W8 (MDA-MB-231-EGFP)CVCL_JG53 (MDA-MB-231-Luc [JCRB])
CVCL_C8W9 (MDA-MB-231-Luc [Ubigene])CVCL_1D88 (MDA-MB-231-luc-D3H1)CVCL_D582 (MDA-MB-231-luc2)
CVCL_V403 (MDA-MB-231-MEK-R)CVCL_5J05 (MDA-MB-231-Red-FLuc)CVCL_5J06 (MDA-MB-231-Red-FLuc-GFP)
CVCL_1D91 (MDA-MB-231-tdTomato)CVCL_S511 (MDA-MB-231/5-FU)CVCL_5T76 (MDA-MB-231/B02)
CVCL_ZZ41 (MDA-MB-231/BCRP)CVCL_C9CE (MDA-MB-231/Cas9-hyg)CVCL_JZ03 (MDA-MB-231/GFP)
CVCL_JZ04 (MDA-MB-231/GFP-RFP)CVCL_JZ05 (MDA-MB-231/Luc)CVCL_YZ80 (MDA-MB-231/Luciferase-2A-RFP)
CVCL_4Z64 (MDA-MB-231/PacR)CVCL_JZ06 (MDA-MB-231/RFP)CVCL_A0YX (MDA-MB-231bo)
CVCL_A0YY (MDA-MB-231br)CVCL_E2QJ (MDA-MB-231cherry)CVCL_4Z65 (MDA-MB-231DR)
CVCL_E2QK (MDA-MB-231GFP)CVCL_M354 (MDA-MB-231LLM)CVCL_XE60 (MDA-MB-231sci)
CVCL_YA89 (MDA-MB-231T)CVCL_4V67 (MDA231-DOX[r])CVCL_VR35 (MDA231-TGL)
CVCL_E0YI (Ubigene MDA-MB-231 DRD2 KO)CVCL_E0YJ (Ubigene MDA-MB-231 FABP5 KO)CVCL_E0YK (Ubigene MDA-MB-231 IL4I1 KO)
CVCL_E0YL (Ubigene MDA-MB-231 LAMTOR5 KO)CVCL_E0YM (Ubigene MDA-MB-231 NLGN4X KO)CVCL_E0YN (Ubigene MDA-MB-231 PKM KO)
CVCL_E0YP (Ubigene MDA-MB-231 RIPK1 KO)CVCL_E0YQ (Ubigene MDA-MB-231 RNF114 KO)CVCL_E0YR (Ubigene MDA-MB-231 SHMT2 KO)
CVCL_E0YS (Ubigene MDA-MB-231 ZNF217 KO)CVCL_YJ68 (VAMPIRO MDA-MB-231)
Sex of cell Female
Age at sampling 51Y
Category Cancer cell line
STR profile Source(s): AddexBio=C0006002/58; ATCC=HTB-26; CCRID; CLS=300275; Cosmic-CLP=905960; DSMZ=ACC-732; ECACC=92020424; KCLB=30026; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351; Technion Genomics Center

Markers:
AmelogeninX
CSF1PO12,13
D1S165615,17
D2S44114,15
D2S133820,21
D3S135816
D5S81812
D7S8208,9
D8S117913
D10S124814,16
D12S39117,18
D13S31713
D16S53912
D18S5111,16
D19S43311,14
D21S1130,33.2 (ATCC=HTB-26; CCRID; CLS=300275; DSMZ=ACC-732; PubMed=28889351; Technion Genomics Center)
33.2 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200)
D22S104516
FGA22,23
Penta D11,14
Penta E11
TH017,9.3
TPOX8,9
vWA15,18 (ATCC=HTB-26; CCRID; Cosmic-CLP=905960; DSMZ=ACC-732; ECACC=92020424; KCLB=30026; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200; PubMed=28889351; Technion Genomics Center)
15,19 (AddexBio=C0006002/58; CLS=300275)

Run an STR similarity search on this cell line
Web pages https://de.wikipedia.org/wiki/MDA-MB-231_(Zelllinie)
https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://www.atcc.org/en/support/technical-support/faqs/morphology-of-atcc-htb-26
https://www.synapse.org/#!Synapse:syn31544482
https://strap.nci.nih.gov/celline_detail.php?sample_id=2
http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-231
http://genome.ucsc.edu/ENCODE/protocols/cell/human/MDA-MB-231_Struhl_protocol.pdf
https://lincs.hms.harvard.edu/resources/reagents/icbp43/
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-394.html
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
https://tcpaportal.org/mclp/
https://www.culturecollections.org.uk/products/cell-cultures/ecacc-cell-line-profiles/mda-mb-231/
https://www.nikonsmallworld.com/galleries/2018-small-world-in-motion-competition/labeling-of-the-microtubule-cytoskeleton-in-a-human-cell-line
https://www.quora.com/What-does-231-stand-for-in-the-MDA-MB-231-cell-line
Publications

PubMed=4412247; DOI=10.1093/jnci/53.3.661; PMCID=PMC7364228
Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.
Breast tumor cell lines from pleural effusions.
J. Natl. Cancer Inst. 53:661-674(1974)

PubMed=1000504
Lippman M.E., Bolan G., Huff K.
The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4595-4601(1976)

PubMed=1000505
Lippman M.E., Bolan G., Huff K.
The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4602-4609(1976)

PubMed=1000506
Lippman M.E., Bolan G., Huff K.
The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.
Cancer Res. 36:4610-4618(1976)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=7000337
Brinkley B.R., Beall P.T., Wible L.J., Mace M.L. Jr., Turner D.S., Cailleau R.M.
Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro.
Cancer Res. 40:3118-3129(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M.
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Cancer Genet. Cytogenet. 3:61-73(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)

PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989
Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.
Mutations in p53 as potential molecular markers for human breast cancer.
Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

PubMed=7902062
de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J.
Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
Anticancer Res. 13:1425-1430(1993)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=9815641
Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E.
Altered gene expression in drug-resistant human breast cancer cells.
Clin. Cancer Res. 3:2405-2414(1997)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=11499871; DOI=10.1359/jbmr.2001.16.8.1486
Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R.
A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
J. Bone Miner. Res. 16:1486-1495(2001)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027
Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P., Clezardin P.
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
J. Bone Miner. Res. 16:2027-2034(2001)

PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105
Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W.
The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Neoplasia 6:187-194(2004)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16049480; DOI=10.1038/nature03799; PMCID=PMC1283098
Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W.-P., Giri D.D., Viale A.J., Olshen A.B., Gerald W.L., Massague J.
Genes that mediate breast cancer metastasis to lung.
Nature 436:518-524(2005)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16417655; DOI=10.1186/bcr1370; PMCID=PMC1413994
Shadeo A., Lam W.L.
Comprehensive copy number profiles of breast cancer cell model genomes.
Breast Cancer Res. 8:R9.1-R9.14(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832
Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17334996; DOI=10.1002/gcc.20438
Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M., Ringner M., Hoglund M., Borg A.
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Genes Chromosomes Cancer 46:543-558(2007)

PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004; PMCID=PMC2391005
Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J.
The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.
Mol. Oncol. 1:84-96(2007)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712
Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.
Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.
Cancer Biol. Ther. 7:699-708(2008)

PubMed=18386134; DOI=10.1007/s10585-008-9169-z
Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S.
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.
Clin. Exp. Metastasis 25:549-557(2008)

PubMed=18714363; DOI=10.1593/neo.08570; PMCID=PMC2517647
Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V., Clezardin P., De Pauw E.A., Castronovo V.
Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells.
Neoplasia 10:1014-1020(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

DOI=10.25904/1912/1434
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010); Griffith University; Brisbane; Australia

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15.1-15.10(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

DOI=10.4172/2157-7145.S2-005
Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21378333
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108
Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428
Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619.1-619.14(2012)

PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33.1-R33.17(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24009699; DOI=10.1371/journal.pone.0072704; PMCID=PMC3751845
Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y.
Cell surface-specific N-glycan profiling in breast cancer.
PLoS ONE 8:E72704-E72704(2013)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776
Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20.1-20.13(2013)

PubMed=24389870; DOI=10.1038/srep03576; PMCID=PMC3880960
Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C.
More than apples and oranges -- detecting cancer with a fruit fly's antenna.
Sci. Rep. 4:3576-3576(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736
Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J.
The proteomic landscape of triple-negative breast cancer.
Cell Rep. 11:630-644(2015)

PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375
Cifani P., Kirik U., Waldemarson S., James P.
Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors.
J. Proteome Res. 14:2819-2827(2015)

PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
J. Chromatogr. B 1000:95-104(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=26649326; DOI=10.1016/j.dib.2015.09.039; PMCID=PMC4644255
Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.
Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism.
Data Brief 5:621-625(2015)

PubMed=27331101; DOI=10.1016/j.dib.2016.05.040; PMCID=PMC4905937
Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K.
Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin.
Data Brief 8:272-279(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

PubMed=29273624; DOI=10.1101/gr.226019.117; PMCID=PMC5793780
Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Genome Res. 28:159-170(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31092827; DOI=10.1038/s41467-019-10148-6; PMCID=PMC6520398
Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S., Andrechek E.R., Chen B.
Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data.
Nat. Commun. 10:2138.1-2138.12(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=32782317; DOI=10.1038/s41598-020-70393-4; PMCID=PMC7419295
Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V.
The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers.
Sci. Rep. 10:13572-13572(2020)

PubMed=34238275; DOI=10.1186/s12885-021-08511-2; PMCID=PMC8268371
Samson J., Derlipanska M., Zaheed O., Dean K.
Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010.
BMC Cancer 21:790.1-790.20(2021)

PubMed=34320349; DOI=10.1016/j.celrep.2021.109441; PMCID=PMC8333195
Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R.
The cancer SENESCopedia: a delineation of cancer cell senescence.
Cell Rep. 36:109441.1-109441.22(2021)

PubMed=35042871; DOI=10.1038/s41523-021-00379-6; PMCID=PMC8766434
Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S.
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.
NPJ Breast Cancer 8:12.1-12.12(2022)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) AddexBio; C0006002/58
ATCC; HTB-26
ATCC; CRM-HTB-26
BCRC; 60425
BCRJ; 0164
CCTCC; GDC0297
CLS; 300275 - Discontinued
DSMZ; ACC-732
ECACC; 92020424
IBRC; C10684
ICLC; HTL99004
IZSLER; BS TCL 223
KCB; KCB 200776YJ
KCLB; 30026
NCBI_Iran; C578
NCI-DTP; MDA-MB-231
Ubigene; YC-D005
Cell line databases/resources CLO; CLO_0007634
CLO; CLO_0037291
MCCL; MCC:0000313
CLDB; cl3402
CLDB; cl3404
CLDB; cl3405
CLDB; cl4945
cancercelllines; CVCL_0062
CCRID; 1101HUM-PUMC000014
CCRID; 3101HUMSCSP5043
CCRID; 3101HUMTCHu227
CCRID; 4201HUM-CCTCC00297
CCRID; 5301HUM-KCB07076YJ
Cell_Model_Passport; SIDM00146
Cosmic-CLP; 905960
DepMap; ACH-000768
DSMZCellDive; ACC-732
FCS-free; 253-2-521-2-3-3
LINCS_HMS; 50058
LINCS_LDP; LCL-1461
Lonza; 815
SKY/M-FISH/CGH; 2815
SLKBase; 3575
TOKU-E; 2394
Anatomy/cell type resources BTO; BTO:0000815
Biological sample resources BioSample; SAMN03472205
BioSample; SAMN05292460
BioSample; SAMN07710033
BioSample; SAMN07710034
BioSample; SAMN07710035
BioSample; SAMN07710036
BioSample; SAMN07710037
BioSample; SAMN07710038
BioSample; SAMN07710039
BioSample; SAMN10987764
CRISP screens repositories BioGRID_ORCS_Cell_line; 554
Chemistry resources ChEMBL-Cells; CHEMBL3307960
ChEMBL-Targets; CHEMBL400
GDSC; 905960
PharmacoDB; MDAMB231_900_2019
PubChem_Cell_line; CVCL_0062
Encyclopedic resources Wikidata; Q17577870
Experimental variables resources EFO; EFO_0001209
Gene expression databases ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-11134
ArrayExpress; E-TABM-157
ArrayExpress; E-TABM-244
GEO; GSM812
GEO; GSM2124
GEO; GSM49953
GEO; GSM49954
GEO; GSM50184
GEO; GSM50248
GEO; GSM69194
GEO; GSM155213
GEO; GSM185093
GEO; GSM185094
GEO; GSM274653
GEO; GSM344349
GEO; GSM344399
GEO; GSM350547
GEO; GSM378148
GEO; GSM388213
GEO; GSM421873
GEO; GSM459713
GEO; GSM481304
GEO; GSM587393
GEO; GSM587394
GEO; GSM750781
GEO; GSM799321
GEO; GSM799384
GEO; GSM820814
GEO; GSM820815
GEO; GSM820816
GEO; GSM839034
GEO; GSM847036
GEO; GSM847401
GEO; GSM844594
GEO; GSM844595
GEO; GSM887295
GEO; GSM888370
GEO; GSM967818
GEO; GSM1008905
GEO; GSM1053716
GEO; GSM1153390
GEO; GSM1172979
GEO; GSM1172889
GEO; GSM1181242
GEO; GSM1181365
GEO; GSM1214569
GEO; GSM1238120
GEO; GSM1374651
GEO; GSM1374652
GEO; GSM1401658
GEO; GSM1613823
GEO; GSM1670080
GEO; GSM1833624
GEO; GSM2095710
GEO; GSM2095711
GEO; GSM2124643
GEO; GSM2258848
GEO; GSM2258849
GEO; GSM2258850
GEO; GSM2258851
GEO; GSM2258852
GEO; GSM2258853
GEO; GSM2258854
GEO; GSM2258855
GEO; GSM2258856
GEO; GSM2258857
GEO; GSM2258858
GEO; GSM2258859
GEO; GSM2258860
GEO; GSM2258861
GEO; GSM2258862
GEO; GSM2258863
GEO; GSM2258864
GEO; GSM2258865
GEO; GSM2258932
GEO; GSM2258933
GEO; GSM2258934
GEO; GSM3161720
GEO; GSM3161721
Metabolomic databases MetaboLights; MTBLS337
MetaboLights; MTBLS387
MetaboLights; MTBLS678
Polymorphism and mutation databases Cosmic; 687494
Cosmic; 871146
Cosmic; 875878
Cosmic; 877450
Cosmic; 894087
Cosmic; 897423
Cosmic; 904377
Cosmic; 905960
Cosmic; 934536
Cosmic; 944294
Cosmic; 974235
Cosmic; 991324
Cosmic; 997929
Cosmic; 1010924
Cosmic; 1018477
Cosmic; 1027053
Cosmic; 1044226
Cosmic; 1046950
Cosmic; 1047693
Cosmic; 1071900
Cosmic; 1092613
Cosmic; 1136369
Cosmic; 1152528
Cosmic; 1175833
Cosmic; 1176602
Cosmic; 1176636
Cosmic; 1183773
Cosmic; 1219444
Cosmic; 1287926
Cosmic; 1289395
Cosmic; 1305383
Cosmic; 1309003
Cosmic; 1312370
Cosmic; 1434952
Cosmic; 1436032
Cosmic; 1466805
Cosmic; 1477428
Cosmic; 1481426
Cosmic; 1524347
Cosmic; 1571793
Cosmic; 1609458
Cosmic; 1927242
Cosmic; 1945862
Cosmic; 1998455
Cosmic; 2009512
Cosmic; 2036667
Cosmic; 2164997
Cosmic; 2301528
Cosmic; 2318377
Cosmic; 2361355
Cosmic; 2560256
IARC_TP53; 6
LiGeA; CCLE_752
Progenetix; CVCL_0062
Proteomic databases PRIDE; PXD000239
PRIDE; PXD000397
PRIDE; PXD000691
PRIDE; PXD000914
PRIDE; PXD001553
PRIDE; PXD002192
PRIDE; PXD002649
PRIDE; PXD005292
PRIDE; PXD005942
PRIDE; PXD005946
PRIDE; PXD008222
PRIDE; PXD010634
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update10-Sep-2024
Version number49